Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185964 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab in Soft Tissue Sarcoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT01185964 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants.
The verdict
NCT01185964, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
Interventions
- DRUG doxorubicin
- BIOLOGICAL Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01185964
The ClinicalTrials.gov registry entry for NCT01185964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin is the first listed.
NCT01185964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01185964 about?
NCT01185964 is a clinical study titled "A Study of Olaratumab in Soft Tissue Sarcoma". The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
What is the current status of trial NCT01185964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2010-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01185964?
The interventions under investigation include: doxorubicin (DRUG), Olaratumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01185964?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.